Gilead Sciences News
News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.
2 hrs ago | Gizmag
Upon approval for use by the US, a generic version of Gilead's HIV drug TAF will be made available to low- and middle-income countries Medicine Patent Pool , a not-for-profit organization, has partnered with pharmaceutical company Gilead Sciences to produce a generic version of a new HIV treatment drug in India and China that will be distributed in ... (more)
11 hrs ago | Examiner.com
Although demand for Gilead Sciences' Solvadi to treat Hepatitis-C is climbing, the fact that it costs $1,000 per 400 mg pill is raising fears that those who need it most may not be able to get it as more and more health insurance companies balk at covering it.
15 hrs ago | TheStreet.com
BOSTON -- A discussion of an experimental hepatitis B therapy kicks off this week's Biotech Stock Mailbag.
Micron is down over 7% today. It is down due to a bad report by Samsung and the possibility of Samsung overbuilding DRAM capacity.
Correspondence: Adrian S. Ray, Gilead Sciences, 333 Lakeside Drive, Foster City, California 94404, USA.
An Oregon Medicaid committee is expected Thursday to significantly scale back access to an effective - but expensive - new drug used to treat hepatitis C. An Oregon Medicaid committee is expected Thursday to significantly scale back access to an effective - but expensive - new drug used to treat hepatitis C. The decision would allow only a narrow ... (more)
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
U.S. health insurers were dragged down by Humana Inc.'s second-quarter earning results, which matched estimates while investors had higher expectations for a boost from Obamacare.
July 29, 2014 -- Gilead Sciences will allow China and Indian drugmakers to start developing generic formulations of a promising novel HIV/HBV drug, even though the drug's Phase III tests are still underway.
Gilead Sciences Director Nicholas G. Moore sold 45,000 shares of the company's stock in a transaction that occurred on Monday, July 28th.
After spending an estimated $16 million this fiscal year on Sovaldi, which holds promise for a cure for the liver-damaging disease, the state agency headed by Julie Hamos approved the restrictions July 10. The rules limit the drug to sicker patients and bar it for anyone with a recent history of drug or alcohol abuse.
At Holdings Channel , we have reviewed the latest batch of the 23 most recent 13-F filings for the 06/30/2014 reporting period, and noticed that Gilead Sciences, Inc. was held by 13 of these funds.
Despite the rally in the stock the shares are still extremely cheap compared to other large cap biotech concerns as well as against other large cap growth plays.
Theraclone Sciences Inc. of Seattle said it's made a deal with Gilead Sciences Inc. that will allow the Foster City-based biotech giant to develop and commercialize Theraclone's neutralizing HIV-antibodies for therapeutic applications in HIV.
A Pause That Depresses: Windstream , CenturyLink , Frontier Communications , Gilead , Merck , Amgen , Twitter , Ford , Schlumberger , Aetna , Cummins , Deere , Monsanto .
Despite a price tag of $1,000 per pill, and $84,000 for a full course of treatment, the new hepatitis C drug Sovaldi has quickly become the therapy of choice for patients infected with the liver-destroying virus, new data shows.
Updated: Fri Aug 01, 2014 07:19 pm
Copyright © 2014 Topix LLC